Tempus AI Adds FDA-Cleared eyonis LCS Lung Cancer AI to Pixel Platform
Tempus AI has partnered with Median Technologies to integrate the FDA-cleared eyonis LCS lung cancer screening AI into its Pixel platform, enhancing nodule detection and malignancy scoring for clinicians. Shares of Tempus AI rose 2.3% post-announcement as the collaboration builds on prior acquisitions to strengthen its imaging-AI portfolio and expand precision medicine revenue potential.
1. Collaboration Details
Tempus AI has formed a partnership with Median Technologies to embed the eyonis LCS lung cancer screening software-as-a-medical-device into the FDA-cleared Pixel imaging platform. The integration enables automated detection and malignancy scoring of lung nodules from CT scans, aiming to streamline radiologist workflows and support earlier disease identification.
2. Clinical Impact and Adoption
The eyonis LCS solution provides both computer-aided detection and diagnosis (CADe/CADx) in a single workflow, generating malignancy risk scores without added complexity. Commercial deployment targets broad clinical adoption to improve screening rates—just 20% of eligible U.S. individuals were screened in 2024—potentially preventing over 62,000 lung cancer deaths in five years.
3. Market Reaction and Positioning
Shares of Tempus AI climbed 2.3% following the collaboration announcement, outperforming a 33.7% six-month share decline compared to a 37% industry drop. With a $9.24 billion market cap, the company leverages this partnership to bolster its imaging-AI portfolio against broader S&P 500 gains of 8.1%.
4. Strategic Growth Outlook
This alliance builds on acquisitions of Arterys and Paige, deepening Tempus AI’s multimodal imaging capabilities and data assets. By expanding its Pixel platform with advanced lung cancer tools, the company aims to drive incremental revenue in AI-enabled precision medicine and enhance long-term competitive positioning.